RxDoctor Payments DataLook up a doctor →

Mark Fleisher

Gastroenterology · Jacksonville, FLNPI 1134125891

Payments from drug & device makers

$1,302,117in general payments, 2019–2025

Across 670 payments — averaging $1943.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$754K
  • Eli Lilly$156K
  • Takeda Pharmaceuticals U.S.A., Inc.$118K
  • Covidien LP$113K
  • Janssen Scientific Affairs, LLC$68K
  • Shire North American Group Inc$65K
  • plus $27K from 39 others
$3,824in research payments, 2019–2025

Across 3 payments — averaging $1274.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

What the payments were for

  • Speaking & faculty fees$53,95073%
  • Travel & lodging$13,23418%
  • Food & beverage$7,16310%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,302,117 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$113,533
Medicare patients
328
Services billed
1,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab26$857,531
LinzessLinaclotide47$51,701
CreonLipase/Protease/Amylase23$48,906
XifaxanRifaximin22$48,430
ZenpepLipase/Protease/Amylase13$30,325
Pantoprazole Sodium793$15,470
Dicyclomine Hcl199$5,328
Mesalamine18$3,701
Famotidine136$3,656
Lubiprostone28$3,271
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl207$2,952
Omeprazole127$2,312
Rabeprazole Sodium11$959
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl31$468
Clarithromycin13$406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$727$857,53126 claims
AbbVieLinzess, Creon$754,104$100,60770 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$531$48,43022 claims
Aimmune Therapeutics, Inc.Zenpep$274$30,32513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →